113 results on '"Ueno, N.T."'
Search Results
2. Combined pathologic‐genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay
3. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer
4. 192MO DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC)
5. 185O Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the randomized, phase III DESTINY-Breast04 trial
6. 432P Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptor–positive metastatic breast cancer in DESTINY-Breast04.
7. Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay
8. 217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
9. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes
10. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival
11. Identifying factors that impact survival among women with inflammatory breast cancer
12. Hematopoietic Stem/Progenitor Cells and Engineering: A PHASE 1, FIRST IN HUMAN (FIH) STUDY OF ADENOVIRALLY TRANSDUCED AUTOLOGOUS MACROPHAGES ENGINEERED TO CONTAIN AN ANTI-HER2 CHIMERIC ANTIGEN RECEPTOR (CAR) IN SUBJECTS WITH HER2 OVEREXPRESSING SOLID TUMORS
13. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment
14. Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al.
15. Incidence of and survival following brain metastases among women with inflammatory breast cancer
16. Circulating tumor cells and bone metastases as detected by FDG–PET/CT in patients with metastatic breast cancer
17. Circulating tumor cells in metastatic inflammatory breast cancer
18. 376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study
19. 689P DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
20. Predictors of Overall Survival among Hormone Receptor Positive Patients with Oligometastatic Breast Cancer
21. 10P Prediction of the 21-gene recurrence score by a non-genomic approach in stage I estrogen receptor-positive, HER2-negative breast cancer
22. 98O The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumour infiltrating lymphocytes (sTIL)
23. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin’s lymphoma
24. Excellent Locoregional Control in Inflammatory Breast Cancer with a Personalized Radiation Therapy Approach
25. Novel combination of AR inhibitor and CDK4/6 inhibitor, MEK inhibitor in non-HR positive breast cancers
26. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma
27. Somatic mutations reveal asymmetric cellular dynamics in the early human embryo
28. Somatic mutations reveal asymmetric cellular dynamics in the early human embryo
29. Landscape of somatic mutations in 560 breast cancer whole-genome sequences
30. Landscape of somatic mutations in 560 breast cancer whole-genome sequences
31. Impact of Statin Use on Outcomes in Triple-Negative Breast Cancer
32. 21 - Novel combination of AR inhibitor and CDK4/6 inhibitor, MEK inhibitor in non-HR positive breast cancers
33. Lack of Breastfeeding History in Parous Women With Inflammatory Breast Cancer Predicts Locoregional Recurrence and Distant Metastasis
34. NSAID Use Reduces Breast Cancer Recurrence in Overweight and Obese Women: Role of Prostaglandin–Aromatase Interactions
35. A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery
36. Risk Factors for Inflammatory Breast Cancer and Other Invasive Breast Cancers
37. Investigator-Initiated Trial for PMDA Approval in Collaboration with the US NCI/CTEP
38. Medical Oncology Training Programs At the University of Texas MD Anderson Cancer Center Need for Clinical Cancer Biologists to Advance the Field of Medical Oncology
39. EZH2 Expression Correlates With Locoregional Recurrence After Radiation in Inflammatory Breast Cancer
40. Medical Oncology Training Programs in the United States
41. Molecular Changes and Targeted Therapy in Inflammatory Breast Cancer
42. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy
43. Comprehensive Post-mastectomy Radiation Therapy (PMRT) in Inflammatory Breast Cancer (IBC) Patients with Limited M1 Disease
44. Pretreatment Staging PET/CT in Patients with Inflammatory Breast Cancer Influences Radiation Treatment Field Designs
45. Gene Expression Profiling of Inflammatory Breast Cancer
46. Triple-Negative/Basal Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer
47. Impact of high-dose chemotherapy on the ability to deliver subsequent local–regional radiotherapy for breast cancer: analysis of cancer and leukemia group B protocol 9082
48. 280: Serological Evidence of Hepatitis C is Associated with Worse Non-Relapse Mortality and Overall Survival after Allogeneic Stem Cell Transplantation
49. 247: High-Dose Chemotherapy with Autologous Stem-Cell Support Versus Standard-Dose Chemotherapy for High-Risk Breast Cancer: Meta-Analysis of Individual Patient Data from 15 Randomized Adjuvant Trials
50. Reduced-intensity conditioning (RIC) regimens result in low prevalence of premature ovarian failure (POF) in women underwent hematopoietic stem-cell transplantation (HST)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.